AI Article Synopsis
- The study explores the effects of three specific polychlorinated biphenyls (PCBs) on the survival of human cervical cancer HeLa cells, revealing that these compounds significantly enhance cell survival over 48 hours.
- Exposure to these PCBs led to increased glycolysis markers, such as elevated glucose consumption and lactate production, indicating that the chemicals stimulate the glycolytic pathway in cancer cells.
- The findings suggest that the upregulation of glycolysis and enhanced cell survival in HeLa cells occur via a mechanism involving the protein PKM2 and ROS production, with potential for antioxidant treatments to counteract these effects.
Article Abstract
It is well known that polychlorinated biphenyls (PCBs) are typical persistent organic pollutants (POPs) in the environment. The present study investigated the effects of three PCBs including 3,3',4,4',5-pentachlorobiphenyl (PCB126), 2,3',4,4',5-pentachlorobiphenyl (PCB118), and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153) on human cervical carcinoma HeLa cell survival and the possible underlying mechanisms. The results showed that PCB126, PCB118, or PCB153 exposure for 48 h significantly promoted HeLa cell survival. Meanwhile, glucose consumption, lactate production, and glycolysis-related proteins including glucose transporter-1 (GLUT1), lactate dehydrogenase (LDHA), and pyruvate dehydrogenase kinase (PDK) were remarkably elevated after three PCBs treatment, indicated PCBs stimulating glycolysis. Moreover, we found that the expression and nuclear distribution of PKM2 protein was significantly increased in PCB126, PCB118, or PCB153-treated HeLa cells. However, the enzymatic activity of PKM2 was reduced. In addition, the three congeners exposure elevated ROS levels and the expression of NADPH oxidase subunits such as NOX2, p47, and p40. The addition of antioxidant NAC antagonized the three PCBs-induced effects on PKM2, cell survival, and glycolysis. Taken together, these results indicated that PCB126, PCB118, or PCB153 exposure promotes cervical cancer HeLa cell survival by PKM2-dependent upregulation of glycolysis, which is mediated by NADPH oxidase-induced ROS production.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15376516.2019.1584658 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
J Clin Oncol
January 2025
Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of China, Shatin, Hong Kong Special Administrative Region, China.
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.
View Article and Find Full Text PDFStudy of the role of transmembrane emp24 domain-containing protein 2 in oral squamous cell carcinoma.
J Appl Oral Sci
January 2025
Ningde Hospital Affiliated to Ningde Normal University, Department of Stomatology, Fujian, China.
Objective: This study aimed to investigate the role of transmembrane emp24 domain-containing protein 2 (TMED2) in oral squamous cell carcinoma (OSCC).
Methodology: A bioinformatics analysis was first conducted to explore TMED2 expression in OSCC and its relation with overall survival. The analysis results were further verified by assessing TMED2 expression levels in human normal oral keratinocyte cells and human OSCC cell lines using quantitative real-time polymerase chain reaction and the Western blot.
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
January 2025
Roswell Park Cancer Institute, Buffalo, NY, United States.
Background: Data in clear cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of HIF1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC.
Patients And Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment).
Serine phosphorylation facilitates protein degradation by the human mitochondrial ClpXP protease.
Proc Natl Acad Sci U S A
February 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
ClpXP is a two-component mitochondrial matrix protease. The caseinolytic mitochondrial matrix peptidase chaperone subunit X (ClpX) recognizes and translocates protein substrates into the degradation chamber of the caseinolytic protease P (ClpP) for proteolysis. ClpXP degrades damaged respiratory chain proteins and is necessary for cancer cell survival.
View Article and Find Full Text PDFchitinase-like protein orchestrates cyst wall glycosylation to facilitate effector export and cyst turnover.
Proc Natl Acad Sci U S A
February 2025
Department of Molecular Microbiology, Washington University in St. Louis, School of Medicine, St. Louis, MO 63130.
bradyzoites reside in tissue cysts that undergo cycles of expansion, rupture, and release to foster chronic infection. The glycosylated cyst wall acts as a protective barrier, although the processes responsible for formation, remodeling, and turnover are not understood. Herein, we identify a noncanonical chitinase-like enzyme TgCLP1 that localizes to micronemes and is targeted to the cyst wall after secretion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!